Bile Duct Cancer Therapeutics Market 2027 by Treatment Type, Type, End User | The Insight Partners

Bile Duct Cancer Therapeutics Market to 2027 - Global Analysis and Forecast by Treatment Type ( Surgical Procedures, Radiation Therapy, Chemotherapy, and Others ); Type ( Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer ); End User ( Hospitals, Ambulatory Surgical Centers, and Others )

Report Code: TIPRE00008766 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming
Covid
MARKET INTRODUCTION

Bile duct cancer develops in the cell lining of bile ducts. The condition is also known as cholangiocarcinoma. According to a research, bile duct cancer is one of the rare forms of cancer. Moreover, an estimated 2,500 new cases of bile duct cancer are diagnosed in the U.S. each year. Changing of skin color to yellow, abdominal pain, itching, weight-loss, and low-grade fever are some of the indications of bile duct cancer. Bile duct therapeutics include surgery, radiation therapy, chemotherapy, photodynamic therapy, and others.

MARKET DYNAMICS

The bile duct cancer therapeutics market is anticipated to grow in the forecast period owing to the rising incidence of bile duct cancer, advanced discoveries and innovations, favorable reimbursement policies, and others.

MARKET SCOPE

The "Bile Duct Cancer Therapeutics Market Analysis to 2027" is a specialized and in-depth study of the pharmaceutical industry with a special focus on the global market trend analysis. The report aims to provide an overview of bile duct cancer therapeutics market with detailed market segmentation by treatment type, type, end user, and geography. The bile duct cancer therapeutics market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading bile duct cancer therapeutics market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION

The global bile duct cancer therapeutics market is segmented on the basis of treatment type, type and end users. Based on treatment type, the market is segmented into Surgical Procedures, Radiation Therapy, Chemotherapy, and Others. Based on type, the market is segmented into intrahepatic bile duct cancer and extrahepatic bile duct cancer. Based on end user, the market is segmented into hospitals, ambulatory surgical centers and others.




Get more information on this report :

REGIONAL FRAMEWORK


The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global Bile Duct Cancer Therapeutics market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Bile Duct Cancer Therapeutics market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting Bile Duct Cancer Therapeutics market from both demand and supply side and further evaluates market dynamics affecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trends. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Bile Duct Cancer Therapeutics market in these regions.




Get more information on this report :

MARKET PLAYERS


The report covers key developments in the Bile Duct Cancer Therapeutics market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from Bile Duct Cancer Therapeutics market are anticipated to lucrative growth opportunities in the future with the rising demand for Bile Duct Cancer Therapeutics market in the global market. Below mentioned is the list of few companies engaged in the Bile Duct Cancer Therapeutics market.

The report also includes the profiles of key Bile Duct Cancer Therapeutics market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.

- Teva Pharmaceutical Industries Ltd.
- Eli Lilly & Company
- Fresenius Kabi Ag
- Celgene Corp
- Pfizer, Inc.
- F. Hoffmann-la Roche Ltd.
- Sanofi
- Boston Scientific Corporation
- Mylan N.V.
- Johnson & Johnson Services Inc.

The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.


Get more information on this report :

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Bile Duct Cancer Therapeutics - By Treatment Type
1.3.2 Bile Duct Cancer Therapeutics - By Type
1.3.3 Bile Duct Cancer Therapeutics - By End User
1.3.4 Bile Duct Cancer Therapeutics - By Region
1.3.4.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. BILE DUCT CANCER THERAPEUTICS LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. BILE DUCT CANCER THERAPEUTICS - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS, RESTRAINTS & EXPECTED INFLUENCE OF COVID-19 PANDEMIC
6. BILE DUCT CANCER THERAPEUTICS - GLOBAL MARKET ANALYSIS
6.1. BILE DUCT CANCER THERAPEUTICS - GLOBAL MARKET OVERVIEW
6.2. BILE DUCT CANCER THERAPEUTICS - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. BILE DUCT CANCER THERAPEUTICS - REVENUE AND FORECASTS TO 2027 - TREATMENT TYPE
7.1. OVERVIEW
7.2. TREATMENT TYPE MARKET FORECASTS AND ANALYSIS
7.3. SURGICAL PROCEDURES
7.3.1. Overview
7.3.2. Surgical Procedures Market Forecast and Analysis
7.4. RADIATION THERAPY
7.4.1. Overview
7.4.2. Radiation Therapy Market Forecast and Analysis
7.5. CHEMOTHERAPY
7.5.1. Overview
7.5.2. Chemotherapy Market Forecast and Analysis
7.6. OTHERS
7.6.1. Overview
7.6.2. Others Market Forecast and Analysis
8. BILE DUCT CANCER THERAPEUTICS - REVENUE AND FORECASTS TO 2027 - TYPE
8.1. OVERVIEW
8.2. TYPE MARKET FORECASTS AND ANALYSIS
8.3. INTRAHEPATIC BILE DUCT CANCER AND EXTRAHEPATIC BILE DUCT CANCER
8.3.1. Overview
8.3.2. Intrahepatic Bile Duct Cancer and Extrahepatic Bile Duct Cancer Market Forecast and Analysis
9. BILE DUCT CANCER THERAPEUTICS - REVENUE AND FORECASTS TO 2027 - END USER
9.1. OVERVIEW
9.2. END USER MARKET FORECASTS AND ANALYSIS
9.3. HOSPITALS
9.3.1. Overview
9.3.2. Hospitals Market Forecast and Analysis
9.4. AMBULATORY SURGICAL CENTERS
9.4.1. Overview
9.4.2. Ambulatory Surgical Centers Market Forecast and Analysis
9.5. OTHERS
9.5.1. Overview
9.5.2. Others Market Forecast and Analysis
10. BILE DUCT CANCER THERAPEUTICS REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Bile Duct Cancer Therapeutics Overview
10.1.2 North America Bile Duct Cancer Therapeutics Forecasts and Analysis
10.1.3 North America Bile Duct Cancer Therapeutics Forecasts and Analysis - By Treatment Type
10.1.4 North America Bile Duct Cancer Therapeutics Forecasts and Analysis - By Type
10.1.5 North America Bile Duct Cancer Therapeutics Forecasts and Analysis - By End User
10.1.6 North America Bile Duct Cancer Therapeutics Forecasts and Analysis - By Countries
10.1.6.1 United States Bile Duct Cancer Therapeutics
10.1.6.1.1 United States Bile Duct Cancer Therapeutics by Treatment Type
10.1.6.1.2 United States Bile Duct Cancer Therapeutics by Type
10.1.6.1.3 United States Bile Duct Cancer Therapeutics by End User
10.1.6.2 Canada Bile Duct Cancer Therapeutics
10.1.6.2.1 Canada Bile Duct Cancer Therapeutics by Treatment Type
10.1.6.2.2 Canada Bile Duct Cancer Therapeutics by Type
10.1.6.2.3 Canada Bile Duct Cancer Therapeutics by End User
10.1.6.3 Mexico Bile Duct Cancer Therapeutics
10.1.6.3.1 Mexico Bile Duct Cancer Therapeutics by Treatment Type
10.1.6.3.2 Mexico Bile Duct Cancer Therapeutics by Type
10.1.6.3.3 Mexico Bile Duct Cancer Therapeutics by End User
10.2. EUROPE
10.2.1 Europe Bile Duct Cancer Therapeutics Overview
10.2.2 Europe Bile Duct Cancer Therapeutics Forecasts and Analysis
10.2.3 Europe Bile Duct Cancer Therapeutics Forecasts and Analysis - By Treatment Type
10.2.4 Europe Bile Duct Cancer Therapeutics Forecasts and Analysis - By Type
10.2.5 Europe Bile Duct Cancer Therapeutics Forecasts and Analysis - By End User
10.2.6 Europe Bile Duct Cancer Therapeutics Forecasts and Analysis - By Countries
10.2.6.1 Germany Bile Duct Cancer Therapeutics
10.2.6.1.1 Germany Bile Duct Cancer Therapeutics by Treatment Type
10.2.6.1.2 Germany Bile Duct Cancer Therapeutics by Type
10.2.6.1.3 Germany Bile Duct Cancer Therapeutics by End User
10.2.6.2 France Bile Duct Cancer Therapeutics
10.2.6.2.1 France Bile Duct Cancer Therapeutics by Treatment Type
10.2.6.2.2 France Bile Duct Cancer Therapeutics by Type
10.2.6.2.3 France Bile Duct Cancer Therapeutics by End User
10.2.6.3 Italy Bile Duct Cancer Therapeutics
10.2.6.3.1 Italy Bile Duct Cancer Therapeutics by Treatment Type
10.2.6.3.2 Italy Bile Duct Cancer Therapeutics by Type
10.2.6.3.3 Italy Bile Duct Cancer Therapeutics by End User
10.2.6.4 Spain Bile Duct Cancer Therapeutics
10.2.6.4.1 Spain Bile Duct Cancer Therapeutics by Treatment Type
10.2.6.4.2 Spain Bile Duct Cancer Therapeutics by Type
10.2.6.4.3 Spain Bile Duct Cancer Therapeutics by End User
10.2.6.5 United Kingdom Bile Duct Cancer Therapeutics
10.2.6.5.1 United Kingdom Bile Duct Cancer Therapeutics by Treatment Type
10.2.6.5.2 United Kingdom Bile Duct Cancer Therapeutics by Type
10.2.6.5.3 United Kingdom Bile Duct Cancer Therapeutics by End User
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Bile Duct Cancer Therapeutics Overview
10.3.2 Asia-Pacific Bile Duct Cancer Therapeutics Forecasts and Analysis
10.3.3 Asia-Pacific Bile Duct Cancer Therapeutics Forecasts and Analysis - By Treatment Type
10.3.4 Asia-Pacific Bile Duct Cancer Therapeutics Forecasts and Analysis - By Type
10.3.5 Asia-Pacific Bile Duct Cancer Therapeutics Forecasts and Analysis - By End User
10.3.6 Asia-Pacific Bile Duct Cancer Therapeutics Forecasts and Analysis - By Countries
10.3.6.1 Australia Bile Duct Cancer Therapeutics
10.3.6.1.1 Australia Bile Duct Cancer Therapeutics by Treatment Type
10.3.6.1.2 Australia Bile Duct Cancer Therapeutics by Type
10.3.6.1.3 Australia Bile Duct Cancer Therapeutics by End User
10.3.6.2 China Bile Duct Cancer Therapeutics
10.3.6.2.1 China Bile Duct Cancer Therapeutics by Treatment Type
10.3.6.2.2 China Bile Duct Cancer Therapeutics by Type
10.3.6.2.3 China Bile Duct Cancer Therapeutics by End User
10.3.6.3 India Bile Duct Cancer Therapeutics
10.3.6.3.1 India Bile Duct Cancer Therapeutics by Treatment Type
10.3.6.3.2 India Bile Duct Cancer Therapeutics by Type
10.3.6.3.3 India Bile Duct Cancer Therapeutics by End User
10.3.6.4 Japan Bile Duct Cancer Therapeutics
10.3.6.4.1 Japan Bile Duct Cancer Therapeutics by Treatment Type
10.3.6.4.2 Japan Bile Duct Cancer Therapeutics by Type
10.3.6.4.3 Japan Bile Duct Cancer Therapeutics by End User
10.3.6.5 South Korea Bile Duct Cancer Therapeutics
10.3.6.5.1 South Korea Bile Duct Cancer Therapeutics by Treatment Type
10.3.6.5.2 South Korea Bile Duct Cancer Therapeutics by Type
10.3.6.5.3 South Korea Bile Duct Cancer Therapeutics by End User
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Bile Duct Cancer Therapeutics Overview
10.4.2 Middle East and Africa Bile Duct Cancer Therapeutics Forecasts and Analysis
10.4.3 Middle East and Africa Bile Duct Cancer Therapeutics Forecasts and Analysis - By Treatment Type
10.4.4 Middle East and Africa Bile Duct Cancer Therapeutics Forecasts and Analysis - By Type
10.4.5 Middle East and Africa Bile Duct Cancer Therapeutics Forecasts and Analysis - By End User
10.4.6 Middle East and Africa Bile Duct Cancer Therapeutics Forecasts and Analysis - By Countries
10.4.6.1 South Africa Bile Duct Cancer Therapeutics
10.4.6.1.1 South Africa Bile Duct Cancer Therapeutics by Treatment Type
10.4.6.1.2 South Africa Bile Duct Cancer Therapeutics by Type
10.4.6.1.3 South Africa Bile Duct Cancer Therapeutics by End User
10.4.6.2 Saudi Arabia Bile Duct Cancer Therapeutics
10.4.6.2.1 Saudi Arabia Bile Duct Cancer Therapeutics by Treatment Type
10.4.6.2.2 Saudi Arabia Bile Duct Cancer Therapeutics by Type
10.4.6.2.3 Saudi Arabia Bile Duct Cancer Therapeutics by End User
10.4.6.3 U.A.E Bile Duct Cancer Therapeutics
10.4.6.3.1 U.A.E Bile Duct Cancer Therapeutics by Treatment Type
10.4.6.3.2 U.A.E Bile Duct Cancer Therapeutics by Type
10.4.6.3.3 U.A.E Bile Duct Cancer Therapeutics by End User
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Bile Duct Cancer Therapeutics Overview
10.5.2 South and Central America Bile Duct Cancer Therapeutics Forecasts and Analysis
10.5.3 South and Central America Bile Duct Cancer Therapeutics Forecasts and Analysis - By Treatment Type
10.5.4 South and Central America Bile Duct Cancer Therapeutics Forecasts and Analysis - By Type
10.5.5 South and Central America Bile Duct Cancer Therapeutics Forecasts and Analysis - By End User
10.5.6 South and Central America Bile Duct Cancer Therapeutics Forecasts and Analysis - By Countries
10.5.6.1 Brazil Bile Duct Cancer Therapeutics
10.5.6.1.1 Brazil Bile Duct Cancer Therapeutics by Treatment Type
10.5.6.1.2 Brazil Bile Duct Cancer Therapeutics by Type
10.5.6.1.3 Brazil Bile Duct Cancer Therapeutics by End User
10.5.6.2 Argentina Bile Duct Cancer Therapeutics
10.5.6.2.1 Argentina Bile Duct Cancer Therapeutics by Treatment Type
10.5.6.2.2 Argentina Bile Duct Cancer Therapeutics by Type
10.5.6.2.3 Argentina Bile Duct Cancer Therapeutics by End User
11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
12. BILE DUCT CANCER THERAPEUTICS, KEY COMPANY PROFILES
12.1. TEVA PHARMACEUTICAL INDUSTRIES LTD.
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. ELI LILLY & COMPANY
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. FRESENIUS KABI AG
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. CELGENE CORP
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. PFIZER, INC.
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. F. HOFFMANN-LA ROCHE LTD.
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. SANOFI
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. BOSTON SCIENTIFIC CORPORATION
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. MYLAN N.V.
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10. JOHNSON & JOHNSON SERVICES INC
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments
13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
The List of Companies

1. Teva Pharmaceutical Industries Ltd.
2. Eli Lilly & Company
3. Fresenius Kabi Ag
4. Celgene Corp
5. Pfizer, Inc.
6. F. Hoffmann-la Roche Ltd.
7. Sanofi
8. Boston Scientific Corporation
9. Mylan N.V.
10. Johnson & Johnson Services Inc.
TIPRE00008766
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Pricing

Free

20%

customization on Pre-Booking